On February 3, 2026 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, reported that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference participation details are as follows:

Noble Emerging Growth Virtual Equity Conference
Date: Thursday, February 5, 2026
Time: 3:00 p.m. ET
Location: Virtual
Investor Registration

IO360° Conference
Date: Thursday, February 12, 2026
Time: 1:20 p.m. – 1:40 p.m. ET
Session: IO Clinical Advancements Plenary
Presentation title: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM

Additional details, including any available webcast information, will be posted on the Events & Presentations section of the Company’s website at www.in8bio.com.

(Press release, In8bio, FEB 3, 2026, View Source [SID1234662427])